Enabling Clinical Grade Manufacturing Of Gene-Engineered NK Cells

Compelling clinical evidence has shown the potential of natural killer (NK) cells for successful adoptive immunotherapy. Moreover, it supports that modifying NK cells with chimeric antigen receptors (CARs) can further enhance their anti-tumor efficacy. Here, we present an automated process for CAR NK cell generation under GMP-compliant conditions and in a closed system with the CliniMACS Prodigy® Instrument.